SCHEMBL7069345

SCHEMBL7069345

CCCC(C(N)=O)C(CC(C)C)C(=O)N1CCN(c2ccc(Cl)c(Cl)c2)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.52
HTT P42858 5/20 0.52
MAPK1 P28482 1/20 0.52
CCR1 P32246 1/20 0.48
SMN1; SMN2 Q16637 7/20 0.48
RAB9A P51151 1/20 0.47
TP53 P04637 2/20 0.47
PANK3 Q9H999 1/20 0.47
CCR3 P51677 2/20 0.43
POLB P06746 1/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
LMNA P02545 3/20 0.43
ALDH1A1 P00352 2/20 0.43
TSHR P16473 2/20 0.43
KDM4E B2RXH2 1/20 0.43
GAA P10253 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
RECQL P46063 1/20 0.43
USP2 O75604 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7069348 1.00 MAPT (0.52) MAPTHTTMAPK1CCR1SMN1; SMN2
SCHEMBL6955151 0.88 NOTUM (0.44)
SCHEMBL7065398 0.88 NOTUM (0.44)
SCHEMBL7068676 0.88 CHIA (0.48) HTTCCR1SMN1; SMN2MEN1KMT2A
SCHEMBL7068679 0.88 CHIA (0.48) HTTCCR1SMN1; SMN2MEN1KMT2A
SCHEMBL7069253 0.87 LMNA (0.55) MAPTHTTMAPK1SMN1; SMN2PANK3
SCHEMBL7069249 0.87 LMNA (0.55) MAPTHTTMAPK1SMN1; SMN2PANK3
SCHEMBL7069855 0.87 ADAMTS5 (0.47) MAPK1LMNATSHRNPSR1RECQL
SCHEMBL7069859 0.87 ADAMTS5 (0.47) MAPK1LMNATSHRNPSR1RECQL
SCHEMBL7068799 0.86 MAPT (0.46) MAPTHTTMAPK1SMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030232985-A1 Succinoylamino heterocycles as inhibitors of a beta protein production THOMPSON LORIN A (US) 2003-12-18 US disclosed
US-20030073701-A1 Succinoylamino heterocycles as inhibitors of a beta protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY 2003-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073701-A1 Succinoylamino heterocycles as inhibitors of a beta protein production APP, BACE1, APH1A MAPT 28/4885HTT 22/4885MAPK1 1873/4885
US-20030232985-A1 Succinoylamino heterocycles as inhibitors of a beta protein production APP, BACE1, APH1A MAPT 28/4885HTT 22/4885MAPK1 1873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.